Icotinib/Gefitinib
Phase 1Small molecule
Icotinib/Gefitinib is one of 53 small molecule programs targeting Advanced NSCLC. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
52
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
60 competitors in Advanced NSCLC
#DrugCompanyPhaseTrials
1Beyfortus
BeiGeneApproved
Tagrisso
AstraZenecaPhase 3
Taxotere
AAvyxa
Phase 3
Paraplatin
AAvyxa
Phase 3
Alimta
SShawn Eagle
Phase 3
Tarceva
OOSI Pharmaceuticals
Phase 3
Keytruda
Merck & Co.Phase 2
Opdivo
Bristol-Myers SquibbPhase 2
Taxol
TevaPhase 2
Avastin
RochePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Icotinib/Gefitinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- FFuzhou General Hospital